Please upgrade your browser.
Impact of hyponatremia on survival of patients with metastatic renal cell carcinoma treated with molecular targeted therapy
Hyponatremia is reported to be associated with poor survival in localized renal cell carcinoma and metastatic renal cell carcinoma treated with immunotherapy.
Increase in Cholesterol Predicts Survival Advantage in Renal Cell Carcinoma Patients Treated with Temsirolimus
Temsirolimus is an effective treatment for renal cell carcinoma. It is associated with increases in serum cholesterol, triglyceride, and glucose. We investigated whether changes of these biomarkers could predict its efficacy.
However, survival is now roughly double what was seen before targeted therapy.
Recent studies using a variety of pharmacological inhibitors and genetic models of HDACs have revealed a central role of HDACs in control of kidney development.
C-reactive protein (CRP) is considered a useful serum marker for patients with RCC. However, its clinical utility in advanced metastatic renal cell carcinoma (AM-RCC), particularly in deciding whether to perform nephrectomy at the onset, is not well studied.
The aim of this study was to evaluate the use of sunitinib as third-line therapy for metastatic renal cell carcinoma (mRCC).
Adaptation to low oxygen by changing gene expression is vitally important for cell survival and tissue development. The sprouting of new blood vessels, initiated from endothelial cells, restores the oxygen supply of ischemic tissues.
The link may be attributed to abnormal stress hormone regulation and inflammatory gene expression, researchers from the University of Texas M.D. Anderson Cancer Center reported in the Aug. 1 edition of PLoS ONE.
Every cancer patient who is diagnosed at CAMC or receives treatment at its hospitals is entered into a computer database.
Isabel Doran is only 4 years old, but she's already had about 15 CT scans â and every one comes with a dose of radiation.
|Powered by NeonCRM|